Announcements - OBI Pharma 台灣浩鼎

2022.Aug.08

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

2022.Aug.08

OBI forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

2022.Aug.08

The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders

2022.Aug.08

OBI’s BOD resolved employees and amount granted for the first issuance of RSU and authorized the decision of record date to the Chairman

2022.Aug.08

The Company's Board of Directors approved the amendment of 2022 Restricted Stock Awards Issuance Rules

2022.Aug.08

Announcement of the Consolidated Financial Statements for the second quarter of 2022 were approved by the Board of Directors

2022.Jul.21

Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China

2022.Jul.04

SUPPLEMENTARY STATEMENTS ON NEWS ARTICLE

2022.Jul.01

The Company announces discontinuation of the Phase II Study of OBI-888

2022.Jun.27

Announcement of the status of implementation of the commitments during the up-listing at Taipei Exchange

News

Latest News

Events

Latest events